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ABSTRACT 
The endothelial protein C receptor (EPCR) plays an important role in cardiovascular disease 
by binding protein C/activated protein C (APC). EPCR structure contains a hydrophobic 
groove filled with an unknown phospholipid needed to perform its function. It is unknown 
whether lipid exchange takes place in EPCR as a regulatory mechanism of its activity. Our 
objective was to identify this phospholipid and to explore the possibility of a lipid exchange 
as a regulatory mechanism of EPCR activity driven by the endothelially expressed secretory 
group V phospholipase A2 (sPLA2-V). We identified phosphatidylcholine (PCh) as the major 
phospholipid bound to human soluble EPCR (sEPCR). PCh in EPCR could be exchanged by 
lysophosphatidylcholine (lysoPCh) and platelet activating factor (PAF). Remarkably, 
lysoPCh and PAF impaired the protein C binding ability of sEPCR. Inhibition of sPLA2-V, 
responsible for lysoPCh and PAF generation, improved APC binding to endothelial cells. 
Accordingly, EPCR-dependent protein C activation and APC antiapoptotic effect were 
significantly enhanced. Endothelial cell supplementation with sPLA2-V resulted in the 
opposite effects. In summary, EPCR accommodates PCh within its hydrophobic groove. 
LysoPCh and PAF impairing EPCR binding properties. sPLA2-V, as a source of these lipids, 
emerges as a potential therapeutic target for patients with inflammatory and thrombotic 
diseases. 
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INTRODUCTION 
The endothelial cell protein C/activated protein C receptor (EPCR) is a transmembrane 
glycoprotein that is abundantly expressed on the surface of the endothelium of the large 
vessels.1 EPCR binds protein C, activated protein C (APC), and factor VII/VIIa (FVII/VIIa) 
with high affinity.2,3 Upon EPCR binding on the endothelial surface, protein C activation by 
the thrombin-thrombomodulin complex is notably increased and factor Xa-dependent FVII 
activation is reduced.4,5 EPCR is a cornerstone molecule in the protein C system which plays 
an important role in cardiovascular pathologies such as thrombosis, coronary artery disease 
and stroke,6-8 and is involved in mechanisms of vascular biology such as inflammation and 
endothelial barrier protection related to sepsis, lung function and metastasis.9,10  
Previous structural studies showed that EPCR folds into two alpha chains which, together 
with a β-sheet platform, conform a hydrophobic groove. This is occupied by a phospholipid 
which has not yet been identified but which is necessary to preserve the ligand binding 
properties of EPCR.11 One of the aims of the present work was to identify the exact nature of 
this phospholipid. Since EPCR shares significant homology with CD1d and MHC-class I like 
molecules which behave as lipid antigen-presenting molecules,12 we speculated that the 
EPCR hydrophobic pocket could be filled with more than one phospholipid. We provide 
evidence that fully active EPCR accommodates phosphatidylcholine (PCh) within its 
hydrophobic groove and that, interestingly, secretory group V phospholipase A2 (sPLA2-V) 
generates bioactive lipids i.e. lysophosphatidylcholine (lysoPCh) and platelet activating 
factor (PAF) in the vicinity of EPCR which, by displacing phosphatidylcholine from the 
hydrophobic groove, notably impair the ability of EPCR to interact with protein C and FVII. 
 
MATERIALS AND METHODS 
An expanded version is available in the Supplemental Methods section.  
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Recombinant proteins expression and purification 
Human and murine yeast-derived sEPCR as well as human mammalian cell-derived sEPCR 
were expressed and purified as described.13-15 
 
Lipid extraction from sEPCR variants and subsequent lipid identification 
The lipid fraction of sEPCR was extracted for subsequent analysis by thin layer 
chromatography (TLC) and mass spectrometry analysis. 
 
Lipid extraction for subsequent analysis of sEPCR function  
n-octyl-β-d-Glucopyranoside was used to extract the lipid from the yeast-derived sEPCR. 
The delipidated sEPCR was subsequently used for surface plasmon resonance (SPR) and 
fluorescence spectroscopy analyses as explained below. 
 
Assessment of the interaction between lipids and sEPCR by fluorescence spectroscopy 
analysis  
The binding of PCh, lysoPCh, PAF and S1P to human delipidated sEPCR was studied by 
measuring the changes in the intrinsic fluorescence of delipidated sEPCR upon incubation 
with increasing amounts of the lipids. The data were used to calculate the dissociation 
constant (KD) for each lipid.   
 
Assessment of the interaction between lysoPCh or PAF and sEPCR by mass 
spectrometry 
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Each lipid was incubated with sEPCR at 10-fold excess. Once the unbound lipid was 
removed by gel exclusion chromatography, the lipid fraction of the eluted protein was 
extracted and analyzed by mass spectrometry.  
 
Biomolecular interaction analyses by SPR 
All interaction experiments were performed by SPR technology using a BIAcore X Biosensor 
(GE Healthcare) basically as previously described.3  
 
Flow cytometry experiments 
All the flow cytometry experiments were performed in a FACScalibur (BD Biosciences). The 
binding of APC to endothelial cells was performed as described.3 The expression of EPCR, 
thrombomodulin and sPLA2-V on the surface of cells was assessed using anti-human EPCR 
RCR-2, anti-human thrombomodulin and anti-human sPLA2-V monoclonal antibodies 
(mAbs) respectively. Apoptosis of staurosporine-stimulated endothelial cells was assessed by 
incubating them with fluorescently-labeled annexin V and actinomicine D.   
 
Activation of protein C on the endothelial surface 
The effect of manoalide and sPLA2-V on APC generation by thrombin on the surface of 
HAEC or EA.hy926 was studied as previously described.13 
 
Immunohistochemical assessment of sPLA2-V expression in tissues  
Sections from carotid arteries from mice subjected to a laser injury-induced thrombosis16 and 
from human left atrial appendages were analyzed for the presence of sPLA2-V using an anti-
sPLA2-V Ab followed by the anti-rabbit Dako Envision+ System-HRP, and for the presence 
of fibrin deposits using Masson’s Trichrome staining.  
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RESULTS 
PCh is the phospholipid located in the hydrophobic pocket of EPCR 
The lipid fraction extracted from yeast-expressed human sEPCR migrated in the TLC plate as 
a single spot exactly as PCh standard did. The same result was obtained using human sEPCR 
produced in mammalian cells, thus suggesting that the lipid naturally occupying the pocket of 
human sEPCR is PCh (Figure 1A). The experiment performed with murine sEPCR revealed a 
major spot corresponding to PCh and a minor one which migrates like PE. 
To further analyze the nature of the EPCR lipid content, the sEPCR organic extract was 
subjected to mass spectrometry analysis which showed a peak at m/z 786, whose 
fragmentation yielded a pattern of peaks that are characteristic of the PCh polar group (Figure 
1B). Commercially available PCh [molecular weight (MW) = 786 Da] rendered the same 
results, as did the lipid extracted from murine sEPCR. Finally, two peaks corresponding to 
two PCh molecules of different MW (786 and 758 Da) were obtained testing human sEPCR 
produced in mammalian cells, and both of them exhibited the characteristic peak pattern of 
the PCh polar group fragmentation. Collectively, these analyses demonstrate that the main 
lipid molecule bound to human EPCR is PCh. 
 
PCh is essential for EPCR to interact with its ligands 
We used SPR technology to analyze whether PCh was necessary to preserve the ability of 
sEPCR to interact with APC. The affinity of EPCR for APC was around 10-times lower when 
PCh was removed from sEPCR (KD = 64 ± 8 and 616 ± 156 nM with and without PCh 
respectively, n = 3) (Figure 2A, 2B), a result that is coherent with previous findings.11 The 
ability of APC to bind to delipidated sEPCR was fully recovered after incubation with PCh 
(Figure 2C). Of note, the KD was 62 ± 27 nM (n = 3), very similar to the obtained with non-
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manipulated sEPCR. Delipidated sEPCR also lost the ability to bind to FVIIa (KD = 83 ± 16 
and 625 ± 147 nM with and without PCh respectively).  
 
LysoPCh and PAF but not S1P can locate in the hydrophobic pocket of EPCR  
Since lysoPCh is derived from PCh and preserves the structure of the latter except that it 
lacks one of the fatty acid groups (Supplemental Figure 1), we speculated that EPCR could 
accommodate it. For this reason we used fluorescence spectroscopy to monitor whether the 
intrinsic fluorescence of delipidated sEPCR changed upon incubation with lysoPCh. As can 
be seen, the three lysoPCh forms tested did modify the intrinsic fluorescence in a dose-
dependent manner (Figure 3A). As a reference, changes in the intrinsic fluorescence of 
delipidated sEPCR were also monitored upon PCh (MW = 760 Da) addition. Interestingly, 
delipidated sEPCR interacted more strongly with all lysoPCh forms than with PCh as shown 
by the KD obtained for each condition: 7.5 ± 8.5, 3.6 ± 1.0, 1.1 ± 0.2 and 108.4 ± 54.5 µM for 
lysoPCh 16:0, 18:0, 18:1 and PCh respectively. Bearing in mind the similarity of PAF and to 
a lesser extent S1P to PCh and LysoPCh (Supplemental Figure 1), we wondered if EPCR 
could accommodate either of these molecules. S1P did not modify the intrinsic fluorescence 
of delipidated sEPCR. However, PAF did modify it, suggesting there was an interaction. 
Interestingly, the affinity was again better than that obtained with PCh (KD = 16.1 ± 12.0 
µM). 
To gain further evidence regarding the interaction between sEPCR and lysoPCh or PAF we 
incubated delipidated sEPCR with lysoPCh (a mixture of 16:0 and 18:0) or PAF, removed the 
excess of lipid by gel exclusion chromatography and extracted the lipid fraction bound to the 
purified protein to subject it to mass spectrometry analysis. Peaks were obtained at both m/z 
496 and 524 in the case of LysoPCh, which correspond to the MW of the lysoPCh molecules 
used in the experiment. Furthermore, the fragmentation spectrum was identical to that 
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obtained with pure lysoPCh 16:0 or 18:0. These results confirm that lysoPCh does bind to 
EPCR (Supplemental Figure 2). In the case of PAF, we detected a peak at m/z 524, which 
corresponds to the molecular weight of PAF, and the fragmentation spectrum was identical to 
that obtained with pure PAF (Supplemental Figure 3).  
 
LysoPCh and PAF displace PCh from the EPCR pocket and impair APC binding 
The finding that these “one-armed” phospholipids bind to EPCR prompted us to determine 
whether the presence of this lipid could alter EPCR interaction with APC. We incubated 
delipidated sEPCR with lysoPCh and observed that, unlike PCh, lysoPCh did not restore the 
ability of delipidated sEPCR to bind to APC (Figure 3B). Finding out whether lysoPCh was 
able to displace PCh from the EPCR hydrophobic groove thus became a particularly 
appealing aim. For this reason we incubated sEPCR (note that in this case sEPCR still retains 
its natural phospholipid) with a 100 molar excess of lysoPCh 16:0, 18:0 or 18:1. Then we 
captured this sEPCR with RCR-2 mAb immobilized on a SPR sensor chip surface in order to 
check its ability to bind to APC. The binding was again notably reduced (Figure 3C), which 
not only provides further evidence that lysoPCh abrogates the EPCR ligand interaction 
properties but interestingly means that lysoPCh is able to actively displace the original lipid 
from the hydrophobic pocket. 
We also examined the effect of PAF on the sEPCR ability to bind to APC. We demonstrated 
that the APC binding ability of delipidated sEPCR was not recovered upon PAF 
reconstitution. The same result i.e. reduced binding, was observed when sEPCR was 
preincubated with 100 molar excess PAF and subsequently tested with immobilized APC 
(Figure 3D).  
 
The binding of APC to EPCR on endothelial cells is modulated by the action of sPLA2-V 
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It was worthwhile at this point to examine whether lysoPCh and PAF were also able to bind 
to EPCR on the cell surface and thus decrease its APC binding efficiency. For this purpose 
we incubated HAEC or EA.hy 926 cells with lysoPCh or PAF for 24 and 48 hours. Flow 
cytometry analyses showed no change in the APC binding capacity (data not shown), 
suggesting that EPCR on the endothelial surface cannot change its original lipid by 
exogenously supplied lysoPCh or PAF, as had previously been demonstrated for the 
homologous CD1d.17 However, whether in situ-produced lysoPCh and PAF were able to 
interact with cell surface EPCR still remained unanswered. LysoPCh and PAF are originated 
by the action of sPLA2-V, which is constitutively expressed by endothelial cells and 
increased by inflammatory stimuli like TNF-α, VEGF and atherosclerosis.18-20 Therefore, 
once we had confirmed that sPLA2-V was expressed in HAEC and EA.hy926 (Supplemental 
Figure 4) we focused on modulating its activity and checking APC binding. Interestingly, the 
blockade of sPLA2-V activity by its inhibitor manoalide increased APC binding to HAEC 
(KD = 71.6 ± 11.1 and 32.7 ± 1.9 nM, p = 0.05, n = 3, in the absence or presence of 
manoalide, respectively). We used 0.5 μM manoalide which was the lower concentration with 
the maximun effect (data not shown). Accordingly, the exogenous addition of sPLA2-V 
decreased APC binding (KD = 330.5 ± 112.6 nM, n = 3, p = 0.05 vs. control, and p = 0.027 
vs. manoalide group) (Figure 4A). We incubated the cells with sPLA2-V for 2 hours because 
this was the time at which the maximum effect was observed (data not shown). Neither 
manoalide nor sPLA2-V modified the EPCR expression on the cell surface (Supplemental 
Figure 5). To rule out the possibility of binding of sPLA2-V to the ligand binding site of 
EPCR we checked by SPR any possible interaction between them and we did not observe any 
binding (data not shown). We performed similar experiments using the EA.hy926 cell line 
and obtained identical results: manoalide significantly enhanced APC binding whereas 
pretreatment with sPLA2-V significantly decreased it, an effect that was reversed by 
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manoalide (Supplemental Figures 6 and 7). Therefore, we provide enough evidence to 
consider that lysoPCh and PAF generated on the cell surface can be accommodated within 
EPCR and that sPLA2-V is a biological modulator of the EPCR function on the surface of the 
endothelial cells. 
 
EPCR ability to increase APC generation on endothelial cells is modulated through 
lipid generation by sPLA2-V 
Since sPLA2-V influences the binding of APC to EPCR on endothelial cells, and protein C 
binds to EPCR similarly to APC i.e. through the Gla domain, we speculated that modulating 
sPLA2-V activity would influence the EPCR-dependent activation of protein C by thrombin 
on the endothelial surface. As expected, activation of protein C on HAEC was significantly 
increased in the presence of manoalide and significantly reduced upon exogenous sPLA2-V 
supplementation (Figure 4B). Flow cytometry experiments showed that thrombomodulin 
expression on the surface of the cells was not influenced by modulation of sPLA2-V activity 
(Supplemental Figure 5). The fact that variations in APC generation were due to differences 
in the Km (control: 136.1 ± 24.5 nM; manoalide: 99.6 ± 9.1 nM, p = 0.05 vs. control; sPLA2-
V: 526.3 ± 173.7 nM, p = 0.037 vs. control) rather than in the Vmax (control: 0.070 ± 0.008 
nM min-1; manoalide: 0.078 ± 0.003 nM min-1; sPLA2-V: 0.068 ± 0.007 nM min-1) conforms 
with an impairment of  protein C binding to EPCR in the presence of sPLA2-V. We obtained 
similar results using EA.hy926 cells and were able to reverse the effect of  sPLA2-V through 
manoalide supplementation (Supplemental Figures 6 and 7). Thus, the anticoagulant activity 
of EPCR on endothelial cells can be modulated by sPLA2-V. 
 
EPCR-dependent antiapoptotic effect of APC on endothelial cells is modulated through 
lipid generation by sPLA-2V 
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APC is known to exert numerous cellular effects through EPCR binding. Among them, the 
prevention of the staurosporine-induced apoptosis of endothelial cells has been well 
characterized. We induced apoptosis in HAEC with staurosporine and observed that the 
antiapoptotic effect of APC was significantly increased up to 125 ± 15% (p = 0.037) upon 
preincubation with manoalide (Figure 4C). Accordingly, supplementation with exogenous 
sPLA2-V significantly decreased the antiapoptotic effect of APC down to 46.6 ± 20.7% (p = 
0.037) (Figure 4C). Under the conditions used in the experiments, sPLA2-V neither increased 
the apoptosis of the cells nor decreased PAR-1 expression (Supplemental Figure 8).
 
Similar 
results were also obtained
 
with
 
EA.hy926 cells (Supplemental Figure 7). These results 
suggest that the inhibitory effects of sPLA2-V go beyond the antithrombotic nature of the 
protein C/APC-EPCR interaction, as it also reduces its cytoprotective properties on 
endothelial cells.
 
 
sPLA2-V is present in thrombi formed in vivo 
Keeping in mind the notable effect of sPLA2-V on EPCR function, we speculated that its 
modulation could play a role in thrombosis. For this reason, we studied the expression of 
sPLA2-V in the carotid arteries of mice within the area close to the thrombus induced by laser 
injury. While we detected neither sPLA2-V nor fibrin in the non-injured carotid arteries 
(Figure 5C, 5D), sPLA2-V expression was abundant in the laser-injured ones: within the 
thrombi, in the neutrophils trapped, and on the endothelial surfaces where thrombi were 
attached (Figure 5A, 5B). Interestingly, we also detected positive sPLA2-V staining in a 
human thrombus formed in the left atrium of a patient with atrial fibrillation as well as on the 
endocardial surface nearby (Figure 5F, 5G), whereas we detected no staining in the left atrial 
endocardium of a donor free of cardiac abnormalities (Figure 5E).  
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DISCUSSION 
EPCR improves the efficiency of protein C activation and is involved in cell signaling 
mechanisms resulting in antiapoptotic, antiinflammatory and endothelial barrier protective 
effects.4,9 When the crystal structure of EPCR was solved, a phospholipid inside its 
hydrophobic groove was found. However, the nature of this phospholipid remained yet to be 
elucidated.11 We provide enough evidence to claim that the major lipid located within the 
hydrophobic pocket of EPCR is PCh. Of note and according to previous studies,11 its removal 
caused a remarkable decrease in APC affinity, which was restored upon PCh 
supplementation. A similar finding was obtained with FVIIa, thus confirming the important 
role played by the phospholipid in ligand binding.3 Our results are consistent with those 
obtained with the highly homologous CD1d, which is also loaded with PCh in its 
hydrophobic groove. Furthermore, a recent “in silico” simulation suggested a relationship 
between the phospholipid binding to EPCR and the size of the surface of interaction with 
protein C, which would be reduced i.e. ligand binding would be worsened, in the absence of 
the phospholipid.21 
The key role played by PCh in EPCR function led us to speculate that its substitution by 
another lipid could influence its ligand binding ability. Lipid exchange occurs in CD1d and 
was anticipated for EPCR in the “in silico” study.21 Among bioactive lipids, lysoPCh exhibits 
a high structural homology with PCh, since it is the product of an enzymatic process that 
removes one of the fatty acids from the latter. Furthermore, lysoPCh binds to CD1d.17,22 For 
these reasons we studied whether EPCR was able to bind to lysoPCh. Among the lysoPCh 
variants, we choose the most abundant ones in human physiology.23 When incubated with 
delipidated EPCR, lysoPCh dose-dependently modified its intrinsic fluorescence. 
Furthermore, the mass spectrometry pattern of the lipid fraction extracted from the 
reconstituted EPCR fully corresponded to lysoPCh. Thus, EPCR is able to accommodate 
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lysoPCh within its hydrophobic groove. Finally, the binding, according to the KD, was 
stronger than that observed with PCh and, of note, remarkably impaired the affinity of EPCR 
for APC and FVIIa (Online Supplemental Discussion). These findings fully conform to the 
“in silico” simulation.21 PAF is a bioactive lipid structurally similar to lysoPCh, also 
generated by endothelial cells, and was able to displace PCh and bind to EPCR as well. 
To find out whether lysoPCh and PAF influenced EPCR function in a more physiological 
condition, we moved to the cellular context. Unlike what happened in the experiments 
performed with sEPCR, there was no change in the EPCR-dependent APC binding when 
lysoPCh or PAF were directly added to endothelial cells. This result initially suggested that 
lipid substitution does not take place when EPCR is on the cell membrane. However, in an 
attempt to be closer to the in vivo condition, we studied whether the EPCR ability to bind to 
APC was modified upon manipulation of sPLA2-V, an endothelially expressed enzyme which 
is the main source of lysoPCh and PAF in that tissue:24 sPLA2-V belongs to the superfamily 
of PLA2 enzymes25 and, being constitutively expressed by endothelial cells, it is upregulated 
by inflammatory stimuli like TNF-α, VEGF or in inflammatory conditions such as 
atherosclerosis. Firstly, we incubated endothelial cells with the PLA2 inhibitor manoalide 
prior to assess APC binding. Unlike what happened when lysoPCh was directly given to 
cells, manoalide did increase the EPCR-dependent binding of APC, and this had to be due to 
the inhibition of sPLA2-V: although manoalide also inhibits sPLA2-IIa and X, the former is 
not present in resting endothelial cells18-20 and the latter is not present either, as we showed 
(Online Figure II). Accordingly, APC binding was notably reduced when endothelial cells 
were supplemented with sPLA2-V. Since SPR experiments made us discard a direct 
interaction between EPCR and sPLA2-V, the most likely explanation for these results is that 
sPLA2-V generates lysoPCh and PAF in the vicinity of EPCR, and the lipids so generated 
displace PCh from EPCR, which in turn partially loses its binding capacity. The fact that a 
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similar mechanism has recently been demonstrated for the highly homologous CD1d 
reinforces our hypothesis.17 
As anticipated, the changes in the functionality of EPCR through sPLA2-V had relevant 
biological consequences i.e. the activation of protein C by thrombin and the antiapoptotic 
effect of APC were impaired as the sPLA2-V activity was increased and viceversa. Thus, a 
new role for sPLA2-V as a downregulator of EPCR function can be proposed, which would 
be specially important in scenarios of inflammation, in which its endothelial expression is 
enhanced. Since APC is one of the cornerstones of the crosstalk between inflammation and 
coagulation, it is interesting that we detected sPLA2-V in the endothelium in situations of 
injury leading to thrombosis, i.e. murine carotid artery, while it was not detected in non-
injured vessels. Furthermore, not only was sPLA2-V detected on the endothelium but also 
inside the thrombus and on the trapped neutrophils, which suggests that sPLA2-V activity was 
increased upon insult, and in turn the locally generated lysoPCh and PAF diminished the 
protein C/APC binding ability of EPCR thus exacerbating the coagulative and inflammatory 
responses in the vicinity of the injured area, thereby facilitating thrombus formation. This 
theory is further substantiated by previous literature supporting a role for thrombin as a 
trigger of the release of lysoPCh by endothelial cells which could be mediated by an increase 
in sPLA2-V expression.26 Furthermore, detection of sPLA2-V in neutrophils and release upon 
cell activation have also been previously reported.27 Finally, the presence of sPLA2-V in the 
left atrial wall, with an attached thrombus, of a patient with atrial fibrillation, suggests that 
our observations can be applied to humans.  
Our findings can be clinically relevant. Overexpression of sPLA2-V would not only reduce 
the amount of APC generated but would also impair the APC-dependent cell signaling 
through the EPCR-PAR-1 axis, thus reducing the APC-associated benefit in a variety of 
settings as endothelial barrier protection, apoptosis reduction, metastasis prevention and 
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others. Also, circulating factor VII levels could become higher since a role for EPCR as a 
scavenger for factor VII, that would be cleared from the circulation, has been demonstrated.28 
Moreover, since we demonstrated that EPCR decreases the activation of FVII by factor Xa,5 
when sPLA2-V was overexpressed, FVIIa generation would be increased thus reinforcing the 
procoagulant properties that our results confer to sPLA2-V.    
In summary, we have demonstrated that the major lipid bound to the hydrophobic groove of 
EPCR is PCh. PCh can be replaced by sPLA2-V-produced lysoPCh or PAF. As a 
consequence, the affinity of EPCR for protein C/APC and factor VII/VIIa decreases, which 
leads to a reduction in the endothelial capacity to generate APC and in the APC-evoked cell 
protective mechanisms. A new prothrombotic/proinflammatory role can be attributed to 
sPLA2-V, which emerges as a promising therapeutic target. Its modulation may help to take 
greater advantage of the anticoagulant and cytoprotective actions of the APC-EPCR axis. 
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 FIGURE LEGENDS 
 
Figure 1. Identification of the phospholipid bound to EPCR. (A) Lane 1, a mixture of PE 
and PCh was loaded as standards. Lane 2, lipid fraction extracted from yeast-produced 
sEPCR. Lane 3, lipid fraction extracted from yeast-produced murine sEPCR. Lane 4, lipid 
fraction from sEPCR produced in a mammalian expression system. (B) MS/MS 
fragmentation analysis of the lipid fraction from yeast-produced sEPCR. The peak at m/z 786 
matches up with commercial PCh. The spectrum generated by fragmentation of the molecule 
at m/z 786 fits properly with commercial PCh. An inset with the different PCh polar group 
fragmentation products and their respective m/z is included. 
 
Figure 2. SPR analysis of the influence of PCh on the APC binding to sEPCR. sEPCR 
was captured on a CM5 chip through RCR-2 mAb. (A) Binding of APC (0, 3, 9, 27, 81 and 
243 nM) to sEPCR. (B) Binding of APC (0, 9, 27, 81, 243 and 729 nM) to delipidated 
sEPCR. In both cases a representative experiment out of three independent repeats is shown. 
Black lines represent experimental data, grey lines represent fittings to a Langmuir 1:1 kinetic 
model. (C) Binding at equilibrium of 100 nM APC to sEPCR, delipidated sEPCR and 
delipidated sEPCR reconstituted with 760 and 786 Da MW PCh. The mean ± standard 
deviation (SD) of three independent experiments are represented. Mann-Whitney U-test was 
used for statistical comparisons.  
 
Figure 3. Binding of lysoPCh to sEPCR. (A) Delipidated sEPCR was incubated with 
increasing amounts of 16:0, 18:0 and 18:1 lysoPCh, 760 Da MW PCh and PAF and the 
change in the sEPCR intrinsic fluorescence was registered. A representative experiment is 
showed for each lipid. (B) SPR analysis of the binding of APC to delipidated sEPCR 
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reconstituted with PCh or lysoPCh. sEPCR or delipidated sEPCR were captured on a CM5 
chip through RCR-2 mAb. Binding at equilibrium of 100 nM APC to sEPCR and to 
delipidated sEPCR preincubated or not with PCh or lysoPCh is shown. The mean±SD of 
three independent experiments are represented. Mann-Whitney U-test was used for statistical 
comparisons. Dlip-sEPCR, delipidated sEPCR. (C) SPR analysis of the binding of APC to 
sEPCR reconstituted with lysoPCh. sEPCR was captured on a CM5 chip through RCR-2 
mAb. Binding at equilibrium of 100 nM APC to sEPCR preincubated or not with different 
species of lysoPCh is shown. The mean ± SD of three independent experiments are 
represented. Mann-Whitney U-test was used for statistical comparisons. (D) SPR analysis of 
the binding of APC to sEPCR reconstituted with PAF. APC-PPACK-b was captured onto a 
SA chip. Binding at equilibrium of 100 nM sEPCR, delipidated sEPCR, PAF-relipidated 
sEPCR and sEPCR preincubated with PAF are shown. The mean±SD of three independent 
experiments are shown. Mann-Whitney U-test was used for statistical comparisons. Dlip-
sEPCR, delipidated sEPCR. 
 
Figure 4. Effect of sPLA2-V on EPCR function on endothelial cells. (A) APC binding to 
HAEC. Cells were incubated with increasing amounts of APC-PP* after 48-hour-
pretreatment with 0.5 µM manoalide (○), 2 hours-pretreatment with 20 µg/mL sPLA2-V (●) 
or no  pretreatment (●). APC-PP* binding was assessed by flow cytometry. A representative 
experiment out of three independent repeats is shown. MEFL means molecules of equivalent 
fluorescein. (B) Protein C activation on HAEC. Increasing amounts of protein C were 
incubated with thrombin for 30 minutes (min) in the presence of HAEC, 48 hours-pretreated 
with 0.5 µM manoalide (○), 2 hours-pretreated with 20 µg/mL sPLA2-V (●), or non-
pretreated (●). The amount of APC generated was measured with the chromogenic substrate 
S-2366. A representative experiment out of three independent repeats is shown. (C) 
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Inhibitory effect of APC on staurosporine-induced apoptosis in HAEC. Cells were pretreated 
with manoalide or sPLA2-V as in A and B, and then supplemented with 50 nM APC for 4 
hours after which apoptosis was induced with 10 µM staurosporine for 60 min. Apoptosis 
was estimated by assessing the number of cells positive for annexin V-Alexa 647 binding by 
flow cytometry. The antiapoptotic effect of APC in the absence of manoalide and sPLA2-V 
was considered 100%. The mean ± SD of three independent experiments are shown. Mann-
Whitney U-test was used for statistical comparisons. 
 
Figure 5. Immunohistochemical detection of sPLA2-V in sections of injured vessels with 
an attached thrombus. (A-D) Carotid artery sections of a mouse subjected to left carotid 
artery laser injury model. Rabbit anti-mouse sPLA2-V Ab (A and C) or Masson’s Trichrome 
for fibrin detection (B and D) were used. (A) sPLA2-V was present in the injured carotid 
artery: in endothelial cells (arrow), neutrophils (arrowhead), vascular smooth muscle cells 
(asterisk) and around fibrin in the lumen. (B) The soft purple staining in the lumen of the 
injured carotid artery revealed the presence of extensive fibrin deposits. (C) There was no 
sPLA2-V in the non-injured carotid artery. (D) Fibrin was not detected in the non-injured 
artery. (E-G) The presence of sPLA2-V was also studied in human left atrial tissue sections. 
(E) sPLA2-V was absent in the atrial sample of a patient in sinus rhythm. (F-G)  sPLA2-V 
was detected around the fibrin thrombus and along the endothelial lining in the atrial section 
corresponding to a patient in atrial fibrillation 





